Financial strategies: Prioritize most evidence-based peptides (Cerebrolysin for glaucoma, Thymosin Beta-4 for corneal issues), use loading dose then reduce to maintenance lowering long-term costs, cycle peptides (8 weeks on, 8 weeks off) versus continuous use, combine with well-established supplements (AREDS2) providing proven value, budget realistically understanding $100-$500 monthly ongoing expense, discontinue if financial burden excessive, focus resources on conventional treatments if limited budget
Coppersmith V, Hudgins S, Stoltzfus J, Stankewicz H
Digestive symptoms are the most common entry point: bloating, abdominal discomfort, and unpredictable bowel habits that seem tied to food but are hard to pin down
That's both the opportunity and the trap: at these prices, the cost difference between a well-tested vial and a poorly tested one is trivial, so there's no reason to accept anything less than a verified COA
Towards a mechanistic understanding of axon transport and endocytic changes underlying paclitaxel-induced peripheral neuropathy
Single-cell transcriptomic and multi-omics analyses have shown that ferroptosis-related gene characteristics are enriched in specific proximal renal tubular subgroups during early type 2 DKD (Tsai et al., 2023
